United States· US:70709-065_fdba8834-a431-46b5-8dd2-5f57fb1efc79
TASCENSO ODT
A medicinal product containing fingolimod lauryl sulfate, registered in United States by Cycle Pharmaceuticals Ltd.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- FINGOLIMOD LAURYL SULFATE
- Manufacturer
- Cycle Pharmaceuticals Ltd
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 1
- ndc1170709-065-30
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c4506e73-33a4-4961-a0a9-55532ac28c06 GET /v1/drugs/c4506e73-33a4-4961-a0a9-55532ac28c06?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": ".5",
"substance": "FINGOLIMOD LAURYL SULFATE",
"productndc": "70709-065",
"dosage_form": "TABLET, ORALLY DISINTEGRATING",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA214962",
"marketing_category": "NDA"
}See everything about fingolimod lauryl sulfate.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.